Overview

Study of Sacituzumab Govitecan-hziy (SG) in Japanese Participants With Advanced Solid Tumors or Triple-negative Breast Cancer

Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
The primary objectives of this study are as follows: Phase 1 (sequential dose-escalation): to evaluate the safety and tolerability of sacituzumab govitecan-hziy (SG) as a single agent and to determine the recommended Phase 2 dose (RP2D) of SG in Japanese participants with advance solid tumors. Phase 2 (dose expansion): to evaluate the efficacy of SG in Japanese participants with triple-negative breast cancer (TNBC).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Gilead Sciences